רטבמו 40 מ"ג - Retevmo 40 mg

• Metastatic RET Fusion-Positive Non-Small Cell Lung CancerRETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).• RET-Mutant Medullary Thyroid CancerRETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy.• RET Fusion-Positive Thyroid CancerRETEVMO is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).• Other RET Fusion-Positive Solid TumorsRETEVMO as monotherapy is indicated for the treatment of adults with advanced RET fusion-positive solid tumors, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted.